Trial Profile
A Randomized Double Blind Placebo Controlled Clinical Study to Assess Blood-Derived Autologous Angiogenic Cell Precursor Therapy in Patients With Critical Limb Ischemia (ACP-CLI)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Feb 2024
Price :
$35
*
At a glance
- Drugs ACP 01 (Primary)
- Indications Chronic limb-threatening ischemia; Peripheral arterial occlusive disorders
- Focus Therapeutic Use
- Acronyms ACP-CLI
- Sponsors Hemostemix
- 06 Feb 2024 According to a Hemostemix media release, results from this study were published in Journal of Biomedical Research and Environmental Sciences.
- 30 Aug 2022 Results presented in a Hemostemix media release.
- 23 Apr 2021 According to a Hemostemix media release, the entry of all subjects information into the clinical trial data base and source document verification processes are ongoing and this is a crucial preliminary step in finalizing the Phase II Clinical Trial.